Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01404247 · ClinicalTrials.gov registry record · Phase 1
Spectral Domain Optical Coherence Tomography Imaging of the Eyes of Neonates
A Phase 1 study of Retinal Diseases and Optic Nerve Diseases, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT01404247 is a Phase 1 study of Retinal Diseases and Optic Nerve Diseases that has completed, run by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. The registered enrollment target is 20 participants, below the 394-participant average among 8 other Retinal Diseases trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01404247, a Phase 1 study of Retinal Diseases and Optic Nerve Diseases, has completed, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Brief Summary The purpose of this study is to better characterize the retina and optic nerve in newborns using spectral domain optical coherence tomography (s-oct). This new technology provides a very detailed cross-section picture of the cellular layers in the retina and a 3-dimensional picture of the optic nerve head and the fovea (the center of the retina that provides the most accurate vision). These images have been used by doctors for more than 5 years to help diagnose and treat adults with eye diseases, such as macular degeneration, diabetic retinopathy, retinal detachments, and melanoma. But, it has never been studied in newborns. In newborns, it would potentially help in the diagnoses of glaucoma, optic nerve hypoplasia, foveal hypoplasia, and colobomata among many other disorders. Prior to diagnosing disorders, it is necessary to establish normal values. It is the purpose of this investigation to study the retina and optic nerves in neonates to establish normal values. After a parent of a normal newborn provides a written consent, the baby will be taken to the Eye Clinic where the instrument is located. The baby will be swaddled in one or more blankets as needed. The infants will be held in front of the instrument by a nurse. The technician will move the lens of the instrument to about 2 to 4 inches from the baby's eye. The mild light from the instrument will then enter the eye for a few seconds to obtain the desired image. The image can be captured through an immobile eye within 5 seconds. If the baby is fussy, he or she may be given a few drops of a sugar (sucrose) solution on a pacifier for calming. Although the images can usually be secured through a normal pupil, if the pupil is found to be too small, two drops of Cyclomydril will be placed on the eye for dilation. This is the eye drop used everyday in the Eye Clinic and nursery to dilate the pupils of babies. The dilation will last for about 6 to 10 hours. After the test, the baby will return to th
Conditions Studied
Interventions
- OTHER Observational: to better characterize the retina and optic nerve in newborns using spectral domain optical coherence tomography (s-oct).
- PROCEDURE OCT imaging.
Study Locations (1)
California
- Los Angeles Biomedical Research Institute atHarbor-UCLA Medical Center - Torrance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-01 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01404247
The ClinicalTrials.gov registry entry for NCT01404247 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 394-participant average among 8 other Retinal Diseases trials with a reported enrollment target (95% lower). The listed sponsor is Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, which has 55 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Retinal Diseases appearing as the primary indexed condition, and to 2 interventions - of which Observational: to better characterize the retina and optic nerve in newborns using spectral domain optical coherence tomography (s-oct). is the first listed.
NCT01404247 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01404247 about?
NCT01404247 is a clinical study titled "Spectral Domain Optical Coherence Tomography Imaging of the Eyes of Neonates". Brief Summary The purpose of this study is to better characterize the retina and optic nerve in newborns using spectral domain optical coherence tomography (s-oct). This new technology provides a very detailed cross-section picture of the cellular layers in the retina and a 3-dimensional picture of...
What is the current status of trial NCT01404247?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2011-01. Estimated completion is 2015-12.
What conditions does trial NCT01404247 study?
This clinical trial studies the following conditions: Retinal Diseases, Optic Nerve Diseases.
What interventions are being tested in trial NCT01404247?
The interventions under investigation include: Observational: to better characterize the retina and optic nerve in newborns using spectral domain optical coherence tomography (s-oct). (OTHER), OCT imaging. (PROCEDURE).
Who is sponsoring clinical trial NCT01404247?
This trial is sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, which has 55 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01404247 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinal Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I Trial of Gene Vector to Patients With Retinal Disease Due to RPE65 Mutations
ACTIVE NOT RECRUITING · Phase 1
-
DISCOVER Study: Microscope-integrated Intraoperative OCT Study
RECRUITING
-
SGLT2 Inhibitors in Geographic Atrophy
RECRUITING · Phase 2
-
4D Duke Microscope Integrated Optical Coherence Tomography in a Zeiss Artevo 800
RECRUITING · NA
-
Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study
ACTIVE NOT RECRUITING
-
Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.